Search Results

Nested Therapeutics today announced that preclinical data from its lead program, NST-628, will be featured in an oral presentation in the “New Drugs on the Horizon” series at the American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 5-10, 2024.

Ora, Inc. announced its participation as a major exhibitor in the Association for Research in Vision and Ophthalmology 2024 conference, and as host and convener of the Dry Horizons Symposium in partnership with Ophthalmology Innovation Source.

Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.

RenovoRx, Inc today announced that Shaun Bagai, RenovoRx’s Chief Executive Officer, will present at the Canaccord Genuity 2024 Horizons in Oncology Virtual Conference to be held on April 15, 2024.

Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a panel on “Breast Cancer – Shifting an Entrenched Paradigm” at the 2024 CG Horizons in Oncology Virtual Conference on Monday, April 15, 2024, at 2:00 p.m. ET.

The company is projecting that future growth will be driven by geographic and label expansions for its rare disease assets, as well as potential approvals in obesity.

OKYO Pharma Limited announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at the Dry Horizons Symposium, a partner meeting of the Association for Research in Vision and Ophthalmology, being held May 3, 2024 in Seattle, WA.

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results.

Horizon Therapeutics plc announced it has been named No. 1 on the Fortune Best Workplaces in Biopharma 2023 list in the large company category.